CN-122005630-A - Extraction method of Cordyceps pseudoblack and medicinal application of extract thereof

Abstract

The invention discloses application of a Cordyceps pseudoacacia extract in preparing a medicament for treating and/or preventing alcoholic liver disease. The Cordyceps pseudoblack extract is prepared by pulverizing Cordyceps pseudoblack material, ultrasonic extracting with water as solvent at 20-45deg.C, collecting extractive solution, concentrating, and drying.

Inventors

• XU PENG
• WANG XIA
• WEI XIN
• SONG JING
• WANG QIANJIN
• LUO JINPING
• ZHANG YONGJIE
• LI SHAOQIN

Assignees

• 山西大学

Dates

Publication Date

20260512

Application Date

20260213

Claims (10)

1. 1. Use of Cordyceps pseudoblack extract in preparing medicine for treating and/or preventing alcoholic liver disease is provided.
2. 2. The use according to claim 1, wherein the extract of Cordyceps pseudoblack contains propranolol-, schizandrin B, glycyrrhizic acid, curcumin, hesperetin, andrographolide, rosmarinic acid, caffeic acid, ursolic acid, corosolic acid.
3. 3. The use according to claim 1 or 2, wherein the Cordyceps pseudoblack extract is prepared by pulverizing Cordyceps pseudoblack material, performing ultrasonic extraction with water as solvent at 20-45deg.C, collecting extractive solution, concentrating, and drying.
4. 4. Use according to any one of claims 1 to 3, wherein the medicament is for reducing the elevation of serum glutamic pyruvic transaminase ALT, glutamic oxaloacetic transaminase AST, alkaline phosphatase AKP, total cholesterol TC and/or triglyceride TG caused by alcoholic liver injury.
5. 5. Use according to any one of claims 1 to 3, wherein the medicament is for increasing the reduction of serum high density lipoprotein cholesterol HDL-C caused by alcoholic liver injury.
6. 6. The use according to any one of claims 1 to 3, wherein the medicament is for ameliorating liver histopathological changes caused by alcoholic liver injury, including reducing hepatic cell steatosis, inflammatory cell infiltration and hepatic cell necrosis.
7. 7. Use according to any one of claims 1 to 3, wherein the amount of the Cordyceps pseudoblack fungus extract administered in the medicament is from 0.1g/kg body weight to 0.3g/kg body weight.
8. 8. The use according to claim 7, wherein the dosage is 0.2g/kg body weight.
9. 9. A pharmaceutical composition for the treatment and/or prevention of alcoholic liver disease comprising a therapeutically effective amount of the extract of Cordyceps pseudolaris prepared by the method of claim 2 or 3 and a pharmaceutically acceptable carrier.
10. 10. The pharmaceutical composition according to claim 9, wherein the content of the Cordyceps pseudoblack extract in the pharmaceutical composition is such that the daily equivalent administration dose for an adult human corresponds to 0.1g/kg body weight to 0.3g/kg body weight of the crude drug.

Description

Extraction method of Cordyceps pseudoblack and medicinal application of extract thereof Technical Field The invention belongs to the technical field of extraction of medicinal components, and particularly relates to an extraction method of cordyceps pseudolaris and medicinal application of an extract thereof. Background With changes in people's lifestyle, the incidence of non-viral liver disease is increasing year by year. The non-viral liver diseases mainly comprise alcoholic liver disease (alcoholicliverdisease, ALD), alcoholic fatty liver disease, non-alcoholic liver disease, drug-induced liver disease, liver cirrhosis, liver cancer and the like, and seriously affect human health. ALD is a main representative of non-viral liver diseases and is also an important cause of other liver diseases, and is usually expressed as fatty liver in the early stage, and further developed into alcoholic hepatitis, liver fibrosis and liver cirrhosis, and clinical symptoms such as hepatocyte necrosis, liver failure and the like can appear when serious, so that the health is seriously endangered. ALD is often caused by long-term overdrinking of patients, and the therapeutic principles of alcoholic liver disease include alcohol withdrawal, nutritional support, disease severity reduction, improvement of early secondary dystrophy, and symptomatic treatment of alcoholic cirrhosis and its complications. Since it is difficult for people suffering from alcohol addiction to achieve complete alcohol withdrawal, the therapeutic effects of some glucocorticoids and other drugs are unsatisfactory and their efficacy varies from patient to patient. Liver transplantation may be an option for patients with poor drug response, but has significant limitations in clinical treatment due to limited organ supply and possible post-transplantation complications. In recent years, natural traditional Chinese medicines play an important role in treating ALD due to multiple targets, strong efficacy and low side effect risk. Some herbal extracts and/or combinations thereof have been shown to be effective in the prevention and treatment of ALD. For example, the bitter orange rhubarb decoction is effective in ameliorating chronic alcoholic liver injury in rats, and the turbidity-resolving and lipid-regulating formulation may alleviate alcoholic liver injury, oxidative stress and inflammation by modulating the Nrf2/Keap1 and MAPKs/NF- κb signaling pathways. The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person of ordinary skill in the art. Disclosure of Invention The invention aims to provide an extraction method of Cordyceps pseudoacacia and medicinal application of the extract thereof, thereby overcoming the defects in the prior art. In order to achieve the above purpose, the invention provides an application of the Cordyceps pseudoacacia extract in preparing a medicament for treating and/or preventing alcoholic liver disease. Cordyceps sinensis is distributed in the south of Shanxi province, and is called as Xiangbang Cordyceps sinensis (CordycepsbarnesiiThwaites) in the prior art. In 2016-2017, the university of shanxi Zhang Yongjie teaches that the correct name of the cordyceps sinensis should be obtained as a pseudo-black cordyceps sinensis (Ophiocordycepsnigrella) by collecting a large amount of cordyceps sinensis samples in shanxi mountain in two years and integrating morphological characteristics and polygenic phylogenetic analysis. At present, the domestic pseudo-black cordyceps only has reports in Shanxi. Cordyceps pseudoblack belongs to eukaryotic kingdom (Eukaryotes), binuclear subgrade (Dikarya), ascomycota (Ascomycota), hypocreales (Sordariomycetes), sarcophytales (Hypocreales) and nemataceae (Ophiocordycipitaceae), and the host is scarab larva (also called grub). A series of biochemical analysis results show that compared with Cordyceps sinensis, the amino acid type and content, ergosterol and mannitol content, mineral element content, cordycepic acid and cordycepin content in the pseudo-black Cordyceps sinensis are similar to or even higher than those of Cordyceps sinensis. In addition, the infrared spectrometry detection result shows that the polysaccharide components in the cordyceps sinensis and the cordyceps sinensis are consistent. The research results show that the Cordyceps pseudoblack has high safety dosage and rich cordycepin content, and has medicinal development value, but the extraction method and the treatment effect on alcoholic liver disease are not clear. The research firstly searches the best extraction method by comparing the content difference of main nutrient substances in the cordyceps pseudolaris after different extraction methods. Then, the protective effect of the cordyceps militaris on the alcoho